Effects of Transcatheter Mitral Valve Repair With MitraClip on Left Ventricular and Atrial Hemodynamic Load and Myocardial Wall Stress by Wijngaarden, S.E. van et al.
Clinical Investigation
Effects of Transcatheter Mitral Valve Repair With MitraClip on
Left Ventricular and Atrial Hemodynamic Load and Myocardial
Wall Stress
SUZANNE ELIZE VAN WIJNGAARDEN, MD,1 VASILEIOS KAMPERIDIS, MD, MSc, PhD,1,2 IBTIHAL AL-AMRI, MD,1
FRANK VAN DER KLEY, MD,1 MARTIN J. SCHALIJ, MD, PhD,1 NINA AJMONE MARSAN, MD, PhD,1
JEROEN J. BAX, MD, PhD,1 AND VICTORIA DELGADO, MD, PhD1
Leiden, The Netherlands; and Thessaloniki, Greece
ABSTRACT
Aims: To evaluate the effects of MitraClip on left ventricular (LV) and left atrial (LA) myocardial wall
stress as assessed with the use of N-terminal pro–B-type natriuretic peptide (NT-proBNP) and strain imaging.
Methods and results: Sixty-five patients with symptomatic moderate and severe mitral regurgitation (MR;
age 75 ± 9 y, 57% male, 89% functional MR) treated with the use of MitraClip were evaluated. Patients
were divided according to 6-month NT-proBNP tertiles. Changes in echocardiographic parameters over 6
months were assessed. Reductions in LV end-diastolic volumes (178 ± 77 mL to 170 ± 79 mL; P = .045)
and LV end-systolic volumes (120 ± 70 mL to 111 ± 69 mL; P = .040) were observed in the overall pop-
ulation. Interestingly, low–NT-proBNP–tertile patients showed slight improvements in LV and LA longitudinal
strain, whereas high–NT-proBNP–tertile patients showed impairment.
Conclusions: Although MitraClip induces hemodynamic unloading in patients with predominantly func-
tional MR, myocardial wall stress is not consistently improved. In patients with reduced NT-proBNP,
improvements in LA volume index and LV and LA strains were observed. Patients who showed an in-
crease in NT-proBNP exhibited impairment in LV and LA strain, suggesting an increase of myocardial wall
stress. (J Cardiac Fail 2018;24:137–145)
Key Words: Mitral regurgitation, transcatheter mitral valve repair, left ventricular function, left atrial function,
left ventricular wall stress, hemodynamic response.
Transcatheter mitral valve repair with the use of the
MitraClip device (Abbott Vascular, Menlo Park, California)
is a minimally invasive alternative to surgery to treat severe
mitral regurgitation (MR) in symptomatic patients with
high operative risk or contraindications for surgery.1 In ad-
dition to MR reduction and improvement of clinical and
functional outcomes, the transcatheter MitraClip implanta-
tion procedure induces hemodynamic unloading with
significant reductions of both left ventricular (LV) and left
atrial (LA) volumes.1–6 Hemodynamic unloading reduces
myocardial wall stretch and theoretically may induce reduc-
tions in N-terminal pro–B-type natriuretic peptide (NT-
proBNP). NT-proBNP is a parameter frequently used in
clinical practice to monitor the treatment of heart failure
patients. In addition, improvements in LV and LA mechan-
ics (strain), measured with the use of 2-dimensional speckle
tracking, can be observed after reductions of myocardial
wall stretch. NT-proBNP and LV and LA strain measured
with the use of speckle tracking echocardiography have
been associated with the prognosis of heart failure patients
and patients with MR.7–11 However, little is known about
the effects of MitraClip on NT-proBNP levels and LV and
LA strain. The present study hypothesized that MitraClip
may induce hemodynamic unloading as reflected by de-
creases in LV and LA volumes, leading to reductions in
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myocardial wall stress as assessed by NT-proBNP and LV and
LA strains.
Methods
Patient Population
All consecutive patients with symptomatic moderate-to-
severe or severe MR who underwent transcatheter mitral valve
repair with the use of the MitraClip device and completed
6-month clinical and echocardiographic follow-up were in-
cluded (Fig. 1). Demographic, clinical, echocardiographic, and
procedural data were prospectively collected in the departmental
information system (EPD-Vision; Leiden University Medical
Center, Leiden, The Netherlands) and retrospectively ana-
lyzed. Patients with incomplete data were excluded. Changes
in plasma levels of NT-proBNP were assessed at 6 months of
follow-up, and the patient population was divided according
to tertiles of NT-proBNPat 6 months. Changes in clinical symp-
toms (NewYork Heart Association [NYHA] functional class,
6-minute walk distance, and quality of life [QoL] according
to the Minnesota Living With Heart Failure questionnaire)12
and echocardiographic parameters of LV and LA dimensions
and functions at 6 months after MitraClip device implanta-
tion were analyzed and compared for each tertile of NT-
proBNP. For retrospective analysis of clinically collected data,
the Institutional Ethical Committee approved this evaluation
and waived the need for patient written informed consent.
Two-Dimensional Echocardiography Data Acquisition
and Analysis
Echocardiography was performed with the patient in the
left lateral decubitus position, with the use of a commercial-
ly available system (E9; General Electric–Vingmed, Horten,
Norway). Images were obtained with the use of a 5MS trans-
ducer in the standard parasternal and apical views. M-mode
and 2-dimensional (2D) color pulsed- and continuous-wave
Doppler data were stored in cine-loop format. Offline anal-
ysis was performed with the use of commercially available
postprocessing data software (Echopac BT13; GE Medical
Systems, Horten, Norway). The mean transmitral gradient
was measured with the use of the continuous-wave Doppler
method. MR grade at baseline was determined according to
current recommendations,13 which include the proximal
isovelocity surface area method and assessment of the vena
contracta by means of 2D color Doppler recordings of the
mitral valve. Residual MR grade at 6 months of follow-up
was quantified as previously described and graded as none
or mild (grade 0–1), moderate (grade 2), moderate to severe
(grade 3), or severe (grade 4).14
Conventional echocardiographic parameters included LV
ejection fraction (LVEF) and LV end-diastolic (LVEDV) and
end-systolic (LVESV) volumes measured in the apical 4- and
2-chamber views according to the biplane Simpson method.15
The LAvolumes were measured on the apical 4- and 2-chamber
views according to the biplane Simpson method and indexed
for body surface area. The maximum LA volume (LAmax)
was measured before the mitral valve opening, the minimum
LA volume (LAmin) at the mitral valve closure and the LA
volume before the atrial contraction (LApreP) at the onset of
the P-wave on the surface electrocardiogram, when sinus rhythm
was present. From these LAvolumes, the LAreservoir, conduit,
and booster pump functions were measured. The LA reservoir
function was calculated as (LAmax − LAmin)/LAmax × 100.
In patients with sinus rhythm, the LA conduit function, re-
flecting passive emptying of the LA, was calculated as (LAmax
− LApreP)/LAmax × 100, and the LA booster pump function,
representing active LA emptying, was calculated as (LApreP
− LAmin)/LApreP × 100.16 With the use of 2D speckle tracking
echocardiography, LV and LAfunctions were assessed (Echopac
BT13).17 LV global longitudinal strain (GLS) was measured on
the apical 4-, 2- and long-axis views and automatically cal-
culated as the average value of the peak systolic strain of each
view. Conventionally, LV GLS is presented as negative values
because myocardial deformation in the longitudinal direc-
tion represents shortening of the myofibers. The reservoir,
conduit, and booster pump function of the LA were assessed
on the apical 4-chamber view with the use of 2D speckle track-
ing echocardiography. The LAreservoir function was measured
as the LA peak longitudinal strain at ventricular systole. In
patients in sinus rhythm, the LA booster pump function was
measured as the LAlongitudinal strain value after P-wave onset.
The LA conduit function was calculated as the difference
between peak systolic LA longitudinal strain and the LA lon-
gitudinal strain value after the P-wave onset (Fig. 2).18,19
Fig. 1. Patient population: CONSORT diagram. MV, mitral valve; NT-proBNP, N-terminal pro–B-type natriuretic peptide.
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Transcatheter Mitral Valve Repair Procedure
Transcatheter MitraClip implantation was performed with
the patient under general anesthesia with the guidance of flu-
oroscopy and transesophageal echocardiography as previously
described.20,21 After trans-septal puncture, the MitraClip was
placed in the LV and the arms of the device were perpen-
dicularly aligned with the coaptation line of the mitral leaflets
at the point with the largest regurgitant jet. If needed, more
than one device was implanted, to ensure MR reduction
without creating valve stenosis. Transcatheter MitraClip im-
plantation success was defined as a reduction of MR to grade
≤2 after deploying one or more MitraClip devices.
Statistical Analyses
All data analyses were performed with the use of SPSS
software version 23.0 (IBM, Armonk, New York). Continu-
ous variables are presented as mean ± SD if normally distributed
or as median (interquartile range [IQR]) if not normally dis-
tributed. Normal distribution was tested with the use of a
Shapiro-Wilk test. Categoric variables are reported as n (%).
Patients were divided according to tertiles of NT-proBNP at
6 months of follow-up. Continuous variables were compared
by means of 1-way analysis of variance (ANOVA), applying
the Bonferroni post hoc analysis, or Kruskal-Wallis 1-way
analysis of variance. Categoric variables were compared by
means of the Fisher-Freeman-Halton exact test. Changes over
time were compared by means of paired t-test or Wilcoxon
signed-rank test for continuous variables. To compare the
changes over time between groups, the absolute differences
of echocardiographic parameters were calculated and com-
pared with the use of 1-way ANOVA and applying the
Bonferroni post hoc analysis. The univariable and multivari-
able correlates of NT-proBNP levels at 6 months of follow-
up were analyzed with the use of linear regressions analysis.
AP value of <.05 was considered to be statistically significant.
Results
Changes in NT-proBNP After MitraClip Implantation
Clinical characteristics of the overall population (mean age
75 ± 9 years, 57% male) are summarized in Table 1. The
majority of the patients had secondary MR (89%). The
transcatheter MitraClip implantation procedure was successful
in 62 patients (95%), and only 3 patients remained with grade
3 MR immediately after the procedure. The majority of pa-
tients received 1 (49%) or 2 (39%) MitraClip devices. During
follow-up after the 6-month clinical and echocardiographic
evaluation, 14 patients were hospitalized owing to worsen-
ing of heart failure and 19 patients died.
In the overall population, no significant changes in NT-
proBNP were observed at 6 months of follow-up (from
2,959 ng/L [IQR 1,271–5,978] to 2,805 ng/L [IQR 1,137–
5,449]; P = .603). Table 2 provides the univariable and
multivariable correlates of NT-proBNP levels at 6 months of
follow-up. Impaired renal function (worse glomerular filtration
Fig. 2. Two-dimensional speckle tracking strain analysis of left atrial (LA) function. The LA reservoir function is measured as the peak
longitudinal strain of the LA myocardium, and the LA booster pump function is measured as the value of longitudinal strain after the P-wave
on the surface electrocardiogram. The difference between peak longitudinal strain and the value of longitudinal strain after the P-wave results
in the LA conduit function (blue double-headed arrow).
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Table 1. Clinical Characteristics of the Total Population and per Tertile of NT-ProBNP at 6 Months of Follow-Up, n (%)
Clinical Variable
All Patients
(n = 65)
Low NT-Pro-BNP
(n = 21)
Medium NT-ProBNP
(n = 230
High NT-ProBNP
(n = 21) P Value
Age, y, mean ± SD 75 ± 9 72 ± 8 78 ± 7 74 ± 10 .086
Male 37 (57%) 12 (57%) 14 (61%) 11 (52%) .950
BSA index, mean ± SD 1.91 ± 0.26 1.97 ± 0.27 1.89 ± 0.22 1.87 ± 0.29 .452
Sinus rhythm 39 (60%) 11 (52%) 12 (52%) 16 (76%) .209
CRT 17 (26%) 4 (19%) 8 (35%) 5 (24%) .528
Prior myocardial infarction 31 (48%) 10 (48%) 12 (57%) 8 (38%) .584
CABG 20 (31%) 9 (42%) 8 (38%) 3 (14%) .122
Previous PCI 30 (46%) 9 (43%) 12 (57%) 7 (33%) .674
Hypertension 32 (49%) 9 (43%) 12 (57%) 10 (48%) .743
Hypercholesterolemia 27 (42%) 11 (52%) 9 (43%) 7 (33%) .307
Diabetes 20 (31%) 9 (45%) 3 (14%) 7 (35%) .114
(Ex-)Smoker 27 (42%) 6 (29%) 11 (48%) 9 (48%) .277
COPD 11 (17%) 3 (14%) 2 (10%) 6 (28%) .242
6-minute walk distance, mean ± SD 342 ± 117 341 ± 129 337 ± 112 292 ± 135 .385
Quality of life, median (IQR) 35 (26–58) 34 (23–50) 31 (19–48) 44 (31–57) .387
eGFR, mL • min−1 • 1.73 m−2, mean ± SD 55 ± 22 65 ± 24 48 ± 15 51 ± 22 .018
NT-proBNP ng/L, median (IQR) 2959 (1271–5978) 1197 (714–3071) 2783 (1917–4160) 6280 (3655–7311) <.001
Log EuroSCORE, mean ± SD 19.8 ± 14.3 17.45 ± 13.76 20.65 ± 14.23 21.11 ± 15.41 .671
Medications
ACEi/ARB 50 (78%) 16 (76%) 19 (90%) 13 (62%) .074
Beta-blocker 54 (83%) 19 (91%) 16 (76%) 17 (81%) .598
Ca2+ channel blocker 6 (9%) 2 (10%) 2 (10%) 1 (5%) .994
Statin 45 (70%) 13 (62%) 15 (71%) 16 (76%) .710
Diuretics 56 (86%) 16 (76%) 20 (95%) 19 (91%) .082
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blockers; BSA, body surface area; CABG, coronary artery bypass graft;
COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; eGFR, estimated glomerular filtration rate; IQR: interquartile range;
NT-proBNP, N-terminal pro–B-type natriuretic peptide; PCI, percutaneous coronary intervention.
Table 2. Univariable and Multivariable Correlates of NT-proBNP Levels at 6 Months of Follow-up (n = 65)
Baseline Variable
Univariable Analysis Multivariable Analysis
B 95% CI P Value B 95% CI P Value
Age 0.442 −0.013 to 0.031 .442
Male −0.063 −0.471 to 0.346 .760
Sinus rhythm 0.321 −0.085 to 0.726 .119
CRT 0.080 −0.380 to 0.540 .730
Previous myocardial infarction −0.185 −0.588 to 0.217 .362
Previous CABG −0.433 −0.858 to −0.009 .046 −0.180 −0.543 to 0.183 .325
Previous PCI −0.124 −0.529 to 0.281 .543
Hypertension −0.062 −0.466 to 0.343 .762
Hypercholesterolemia −0.317 −0.720 to 0.086 .121
Diabetes −0.212 −0.584 to 0.160 .259
(Ex-)Smoker 0.078 −0.149 to 0.304 .496
COPD 0.328 −0.205 to 0.862 .223
6-minute walk distance −0.001 −0.003 to 0.001 .211
Quality of life 0.004 −0.006 to −0.014 .388
eGFR −0.010 −0.019 to −0.001 .037 −0.008 −0.016 to 0.000 .042
NT-proBNP per 10 ng/L 0.001 0.000 to 0.001 .004 0.001 0.000 to 0.001 .008
Log EuroSCORE 0.006 −0.008 to 0.020 .413
No. of implanted MitraClip 0.156 −0.104 to 0.415 .236
LVEF −0.010 −0.024 to 0.004 .150
LVEDV 0.004 0.001 to 0.006 .003 0.003 0.001 to 0.005 .004
LVESV 0.004 0.001 to 0.007 .005
LV longitudinal strain 0.024 −0.016 to 0.064 .244
LA volume index 0.004 −0.003 to 0.012 .254
LA reservoir function volumetric −0.008 −0.026 to 0.011 .394
LA conduit function volumetric −0.028 −0.058 to 0.001 .060
LA booster pump function volumetric −0.013 −0.041 to 0.015 .339
LA reservoir strain volumetric −0.011 −0.060 to 0.038 .654
LA conduit strain volumetric 0.028 −0.108 to 0.164 .679
LA booster pump strain volumetric −0.034 −0.097 to 0.028 .277
Transmitral gradient 0.191 0.044 to 0.339 .012 0.138 0.015 to 0.261 .029
Peak tricuspid regurgitant gradient 0.026 0.008 to 0.044 .006 0.010 −0.006 to 0.025 .226
LA, left atrial; LV, left ventricular; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-
systolic volume; other abbreviations as in Table 1.
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rate), higher levels of NT-proBNP, larger LVEDV, and higher
transmitral gradient at baseline were associated with higher
levels of NT-proBNP at 6 months of follow-up.
When dividing the patients into groups according to the
tertiles of NT-proBNP at 6 months’ follow-up, NT-proBNP
at follow-up showed a significant decrease (P = .046) in pa-
tients within the low NT-proBNP tertile, remained stable
(P = .670) in patients within the medium NT-proBNP tertile,
and showed a significant increment (P = .014) in patients
within the high NT-proBNP tertile compared with baseline
(Fig. 3). When dividing the population according to 6-month
NT-proBNP tertiles, there were no differences in demograph-
ic and clinical characteristics at baseline (Table 1). At 6
months of follow-up, successful MR reduction was more
often accomplished in patients within the low and medium
NT-proBNP tertiles, with only 14% and 13% of patients, re-
spectively having grade ≥3 MR, whereas among patients
within the high NT-proBNP tertile, 43% remained with grade
≥3 MR (P = .046). High–NT-proBNP–tertile patients more
often received 3 or 4 MitraClip devices (5 [23%]) com-
pared with those in the low and medium tertiles (1 [5%] and
2 [8%], respectively; P = .233).
Changes in Clinical Symptoms at 6 Months of
Follow-Up
In the overall population, there were significant improve-
ments in NYHA functional class (the number of patients with
NYHA functional class ≥III decreased from 42 [65%] to 11
[17%]; P = .011) and QoL score (from 35 [IQR 26–58] to 27
[9–43]; P = .005). Information on 6-minute walking dis-
tance was complete for all patients but 13. There were no
changes in the 6-minute walking distance (321 ± 137 m to
357 ± 122 m; P = .144). When analyzing the data according
to 6-month NT-proBNP tertiles, significant reductions in
NYHA functional class symptoms (Fig. 4) and QoL score were
observed among the patients within the low and medium NT-
proBNP tertile groups (QoL score from 34 [IQR 23–50] to
24 [6–41; P = .020] and 31 [19–48] to 15 [8–26; P = .009],
respectively). In contrast, QoL did not show significant changes
in the patients within the high NT-proBNP tertile. No sig-
nificant changes were observed in the 6-minute walking
distance in any group.
Changes in LV and LA Dimensions and Function on
Conventional Echocardiography
The baseline echocardiographic characteristics for the overall
population and for the 6-month tertiles of NT-proBNP are sum-
marized in Table 3. Patients within the high NT-proBNP tertile
showed significantly larger LVEDV and LVESV compared
Fig. 3. Changes in NT-proBNP according to tertiles of NT-
proBNP at 6 months of follow-up. Legends: *P < .05 baseline vs
6 months. †P < .05 vs low NT-proBNP. §P < .05 vs middle NT-
proBNP. NT-proBNP, N-terminal pro–B-type natriuretic peptide.
Fig. 4. Changes in New York Heart Association (NYHA) functional class according to the NT-proBNP tertiles at 6 months of follow-up.
NT-proBNP, N-terminal pro–B-type natriuretic peptide.
MitraClip on LV and LA Hemodynamics and Wall Stress • van Wijngaarden et al 141
with the other groups. In addition, patients in the high
NT-proBNP tertile had a significantly higher mean transmitral
gradient and tricuspid regurgitant jet velocity compared with
the other groups. In the overall population, a significant re-
duction in LVEDV (from 178 ± 77 mL to 170 ± 79 mL;
P = .045) and LVESV (from 120 ± 70 mL to 111 ± 69 mL;
P = .040) was noted at 6 months of follow-up without sig-
nificant changes in LVEF (from 37 ± 14% to 39 ± 14%;
P = .138). Furthermore, there were no significant changes
in LA volume index (from 68 ± 26 mL/m2 to 70 ± 31 mL/m2;
P = .321) or volumetric LA functions (reservoir: 29 ± 10% to
29 ± 11% [P = .650]; conduit: 17 ± 9% to 14 ± 9% [P = .051];
booster pump: 17% [IQR 10–24] to 16 [10–28; P = .404]).
Similarly, there were no significant changes in LV volumes
and LVEF in any of the 6-month NT-proBNP tertiles (Fig. 5).
However, LA volume index decreased in patients within the
low 6-month NT-proBNP tertile and significantly increased
in the high 6-month NT-proBNP tertile (from 74 ± 34 mL to
83 ± 38 mL; P = .041). Finally, no changes were observed
in any of the volumetric measurements of LA function
Table 3. Conventional Echocardiographic Parameters at Baseline per 6-Month NT-Pro-BNP Group
Echocardiographic Variable
Low NT-ProBNP
(n = 21)
Medium NT-ProBNP
(n = 23)
High NT-ProBNP
(n = 21) P Value
LV parameters
LVEF (%) 39 ± 15 39 ± 14 33 ± 14 .247
LVEDV (mL) 149 ± 48 170 ± 70 219 ± 93*,† .008
LVESV (mL) 95 ± 43 108 ± 61 155 ± 88*,† .012
LA parameters
LA volume index mL/m2 65 ± 15 64 ± 24 74 ± 34 .414
LA reservoir function volumetric (%) 29.6 ± 12.3 30.3 ± 10.4 26.7 ± 10.1 .520
LA conduit function volumetric (%) 21.5 ± 11.4 17.0 ± 5.4 14.9 ± 8.3 .162
LA booster pump function volumetric (%) 20.6 (13.2–27.9) 15.6 (8.2–27.3) 15.4 (8.9–21.3) .645
Transmitral gradient (mm Hg) 1.16 (0.92–2.26) 1.68 (1.05–2.67) 1.87 (1.44–3.36)†,* .013
Peak tricuspid regurgitant gradient (mm Hg) 29 ± 7 35 ± 10 38 ± 12* .021
Abbreviations as in Tables 1 and 2.
*P < .05 vs low NT-proBNP.
†P < .05 vs medium NT-proBNP.
Fig. 5. Graphic display of the development (baseline vs 6-month follow-up) of left ventricular (LV) and left atrial (LA) volumes and func-
tion by both volumetric and 2-dimensional speckle tracking strain analyses. P values indicate the significance of the comparison of absolute
changes over time for each echocardiographic parameter across the groups. LVEF, left ventricular ejection fraction; LVESV, left ventricular
end-systolic volume. NT-proBNP, N-terminal pro–B-type natriuretic peptide. LV global longitudinal strain (GLS) corrected for LVESV and
LA booster strain are shown as median and interquartile range. The other variables are shown as mean and standard error. *P < .05 baseline
vs 6 months.
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across the 6-month NT-proBNP tertiles. All groups showed
a significant increase in mean transmitral gradient at 6
months of follow-up with a similar distribution; high–NT-
proBNP–tertile patients exhibited higher gradients compared
with the low and medium tertiles (4.49 [IQR 2.37–6.69], 3.69
1.95–4.35], and 3.99 [2.88–5.03], respectively; P = .204),
though without achieving statistical significance.
LV and LA Function in 2D Speckle Tracking Strain
Analyses
In the overall population, LV GLS did not change signifi-
cantly at 6 months of follow-up (from −9.8 ± 5.1% to
−9.5 ± 4.3%; P = .398). However, LV GLS slightly im-
proved in patients within the low NT-proBNP tertile (from
−10.4 ± 5.2% to −11.3 ± 4.3%; P = .245), remained un-
changed in patients within the medium NT-proBNP tertile
(from −10.4 ± 5.0% to −10.0 ± 3.7%; P = .205), and signifi-
cantly worsened in patients within the high NT-proBNP tertile
(from −8.6 ± 8.0% to −7.0 ± 3.9%; P = .036).
In the overall population, only LA conduit function de-
creased significantly (from 7.0 ± 2.1% to 5.5 ± 2.7%; P = .003)
whereas LA reservoir and booster pump functions remained
unchanged (from 11.7 ± 4.1% to 11.3 ± 5.5% [P = .483] and
from 4.5% [IQR2.0–7.5] to 5.3% [2.0–10.6; P = .120], re-
spectively). When analyzing the data according to 6-month
NT-proBNP tertiles, patients within the low NT-proBNP tertile
showed significant improvement in both LA reservoir and LA
booster pump functions (from 11 ± 4% to 14 ± 6% [P = .025]
and from 5% [IQR 2–9] to 9% [5–12; P = .026], respective-
ly), whereas LA conduit function did not change (Fig. 5).
Patients within the medium NT-proBNP tertile showed no sig-
nificant changes in LA reservoir and booster pump functions,
but did show a decline in LA conduit function (from 8 ± 2%
to 6 ± 2%; P = .047), whereas in patients within the high NT-
proBNP tertile, all LA functions assessed by means of strain
analysis showed significant decline (reservoir from 11 ± 3%
to 8 ± 3% [P = .013], conduit from 7 ± 2% to 5 ± 2%
[P = .041], and booster from 4% [IQR 2–5] to 1% [1–4;
P = .037]; Fig. 5).
Discussion
The present study demonstrates a wide range in NT-
proBNP response 6 months after MitraClip implantation.
Clinically, patients within the high NT-proBNP tertile
showed less improvement in symptoms than patients in the
low tertile. Echocardiographically, patients within the low
NT-proBNP tertile showed significant reductions in LA volume
indexes and improvement in LA reservoir and booster
pump functions (as assessed with the use of 2D speckle track-
ing echocardiography), whereas patients within the high
NT-proBNP tertile showed impairment in LV systolic
function (based on LV GLS measures), an increase in LA
volume indexes, and impairment in LA reservoir and booster
pump functions.
Effects of MitraClip on NT-proBNP
NT-proBNP is an important prognostic biomarker in heart
failure patients.8,9 In patients with significant MR, MitraClip
implantation reduces the regurgitant volume, resulting in he-
modynamic unloading and reduction of myocardial wall
stretch. These changes would result in parallel reductions in
NT-proBNP. However, this theory has not been consistently
demonstrated across the studies.22–27 For example, in the study
by Schau et al including 194 patients (73% with functional
MR) treated with the use of MitraClip and a 93% procedur-
al success rate (defined as reduction in MR to grade ≤2), 21%
of patients remained with NT-proBNP levels ≥10,000 pg/mL.26
In addition, Yoon et al reported nonsignificant reductions in
NT-proBNP after successful MitraClip implantation in 144
patients with severe MR (from 2,942 (IQR 1,596–5,722) to
2,739 (1,440–4,296) ng/L; P = .21).25 These results are con-
sistent with those of the present study. Potential confounders
that alter the changes in NT-proBNP after MitraClip could
include renal function, body weight, and underlying LV sys-
tolic dysfunction.28 Indeed, multivariable analysis showed that
worse renal function, larger LVEDV, and higher transmitral
gradient after MitraClip implantation were independently as-
sociated with higher levels of NT-proBNP at follow-up.
Patients who remain with increased levels of NT-proBNP have
shown increased mortality rates at follow-up compared with
patients with lower values.26 However, little is known about
the association between changes in NT-proBNP and changes
in LV and LA dimensions and function.
Effects of MitraClip on LV and LA Dimensions and
Function
From the EVEREST II clinical studies (including the ran-
domized controlled trial, the single-arm EVEREST II High-
Risk Study, and the continued access study of the EVEREST
II–REALISM), it has been shown that MitraClip implanta-
tion results in reduction in LV and LA volumes without
changes in LVEF at 12 months of follow-up.5 The volumet-
ric reverse remodeling is more pronounced in the absence of
residual MR, whereas the reduction in LV and LA volumes
is minimal when significant MR persists.5 The results of the
GRASP (Getting Reduction of Mitral Insufficiency by Per-
cutaneous Clip Implantation) registry showed significant
reductions in LV and LA volumes and improvement in LVEF
at follow-up.29 Similarly to the EVEREST II studies,5 the
present study showed significant reductions in LVEDV and
LVESV without changes in LVEF whereas LA volume index
and functions remained unchanged.
Integrating NT-ProBNP and Echocardiographic
Changes After MitraClip
This study integrated the NT-proBNP response after
MitraClip implantation with the clinical and echocardiographic
responses. Despite significant reductions in LV volumes in
the overall population, NT-proBNP remained unchanged. Fur-
thermore, based on 2D speckle tracking analysis, no changes
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in LV GLS were observed in the overall population, whereas
LA conduit function decreased. The present study investi-
gated which parameters can lead to disparate clinical,
biochemical, and echocardiographic responses by dividing the
population into tertiles of NT-proBNP at follow-up. Implan-
tation of the MitraClip device leads to a change in mitral
function and unloading of the left ventricle. The relative
increase in the transmitral gradient may affect the function
of the left atrium, which may be severely diseased at base-
line. This is particularly likely among patients with high NT-
proBNP tertile at 6 months of follow-up, in whom the LA
functions were impaired based on conventional and speckle
tracking echocardiographic analyses. Most likely, the extent
of fibrosis in the LA and LV myocardium is an important de-
terminant for response to MitraClip implantation, because in
patients with more myocardial fibrosis, relief of myocardial
wall stretch may not occur. Patients within the low NT-
proBNP tertile showed better LV GLS compared with patients
within the high tertile NT-proBNP subgroup. LV GLS has been
shown to reflect LV myocardial fibrosis in heart failure
patients30,31 and more impaired LV systolic function than LVEF
in patients with functional MR.32 Therefore, LV GLS may be
a valuable surrogate to characterize the changes in LV func-
tion in patients treated with the use of MitraClip.
When assessing LV dysfunction in patients with MR it is
important to acknowledge differences between secondary
and primary MR. The latter is caused by intrinsic lesions of
the mitral valve apparatus, and in eliminating MR, the he-
modynamic burden that causes LV dysfunction is resolved.33,34
However, secondary MR is caused by a diseased LV, and treat-
ment of MR will not completely correct the underlying
cause and LV function may not improve.33 NT-ProBNP
may be a valid surrogate to identify the patients with less
myocardial fibrosis of the LA and LV and who may better
respond in terms of clinical symptoms and echocardiographic
parameters. In the present analysis, patients with clinical
and echocardiographic improvements had lower baseline
NT-proBNP values, and, in contrast, those who showed less
improvement or even deterioration had higher baseline values.
Whether baseline NT-proBNP values are useful in risk strat-
ification of patients undergoing MitraClip procedure needs
further investigation.
Study Limitations
This is a single-center retrospective study with a relatively
small number of patients. However, this is so far the largest
study with combined assessment of conventional and advanced
echocardiography together with assessment of NT-proBNP
levels at follow-up, and adds further to our understanding of
potential benefits of MitraClip implantation. The strain mea-
surements were performed with the use of commercially
available software, and the results may not be comparable to
those obtained with the use of other platforms. Quantifica-
tion of residual MR after MitraClip implantation remains
challenging. We performed a qualitative assessment because
a volumetric assessment would not be accurate owing to some
patients having concomitant aortic regurgitation.
Conclusion
Changes in NT-proBNP after MitraClip implantation vary
widely. In patients who showed a reduction in NT-proBNP,
reductions in LA volume indexes and improvement in LV GLS
and LA strain were observed. In contrast, patients who showed
an increase in NT-proBNP exhibited impairment in LV GLS
and LA strain, suggesting an increase of myocardial wall stress.
Additional studies are needed to better understand which pa-
tients would improve in terms of hemodynamic unloading and
relief of myocardial wall stretch after MitraClip implantation.
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